158 related articles for article (PubMed ID: 16724522)
21. Inhibitors of dopamine inactivating systems as antiparkinson drugs.
Youdim MB
Adv Neurol; 1990; 53():483-8. PubMed ID: 2239488
[No Abstract] [Full Text] [Related]
22. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
Lees AJ; Tolosa E; Olanow CW
Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
[TBL] [Abstract][Full Text] [Related]
23. Parkinson's goal: ease symptoms, slow progression.
Johns Hopkins Med Lett Health After 50; 2006 Jun; 18(4):4-5. PubMed ID: 16795901
[No Abstract] [Full Text] [Related]
24. [Pharmacotherapy and guidelines].
Baas H
Pharm Unserer Zeit; 2006; 35(3):242-8. PubMed ID: 16724528
[No Abstract] [Full Text] [Related]
25. Thirty five years of experience in the treatment of Parkinson's disease with levodopa and associations.
Chouza C; Buzó R; Scaramelli A; Romero S; de Medina O; Aljanati R; Dieguez E; Lisanti N; Gomensoro J
J Neural Transm Suppl; 2006; (70):427-31. PubMed ID: 17017563
[No Abstract] [Full Text] [Related]
26. Current topics in brain dopamine research: a tribute to Professor Oleh Hornykiewicz.
Pifl C; Sperk G
Wien Klin Wochenschr; 2006 Oct; 118(19-20):563-5. PubMed ID: 17136327
[No Abstract] [Full Text] [Related]
27. The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future.
Fahn S
Parkinsonism Relat Disord; 2018 Jan; 46 Suppl 1():S1-S5. PubMed ID: 28784297
[TBL] [Abstract][Full Text] [Related]
28. Levodopa. Is toxicity a myth? 1998.
Agid Y
Neurology; 2001 Nov; 57(10 Suppl 3):S46-51. PubMed ID: 11775601
[No Abstract] [Full Text] [Related]
29. The history of Parkinson's disease: early clinical descriptions and neurological therapies.
Goetz CG
Cold Spring Harb Perspect Med; 2011 Sep; 1(1):a008862. PubMed ID: 22229124
[TBL] [Abstract][Full Text] [Related]
30. Milestones in Parkinson's disease therapeutics.
Rascol O; Lozano A; Stern M; Poewe W
Mov Disord; 2011 May; 26(6):1072-82. PubMed ID: 21626552
[TBL] [Abstract][Full Text] [Related]
31. The history of dopamine and levodopa in the treatment of Parkinson's disease.
Fahn S
Mov Disord; 2008; 23 Suppl 3():S497-508. PubMed ID: 18781671
[TBL] [Abstract][Full Text] [Related]
32. [Treatment in Parkinson disease].
Takáts A
Orv Hetil; 2004 Apr; 145(15):833-4. PubMed ID: 15188639
[No Abstract] [Full Text] [Related]
33. Guideline for the treatment of Parkinson's disease.
Carr J; Kies B; Fine J;
S Afr Med J; 2009 Oct; 99(10):755-6, 758. PubMed ID: 20128276
[No Abstract] [Full Text] [Related]
34. 200 Years of Parkinson's disease: what have we learnt from James Parkinson?
McDonald C; Gordon G; Hand A; Walker RW; Fisher JM
Age Ageing; 2018 Mar; 47(2):209-214. PubMed ID: 29315364
[TBL] [Abstract][Full Text] [Related]
35. [2011: not just PRAXIS, also dopa turns 100 years old...].
Ludin HP
Praxis (Bern 1994); 2011 May; 100(10):573-4. PubMed ID: 21661277
[No Abstract] [Full Text] [Related]
36. The fabulous neuroprotection of selegiline: memoir and prospectus.
Landau WM
J Child Neurol; 2010 Oct; 25(10):1302-4. PubMed ID: 20940135
[No Abstract] [Full Text] [Related]
37. Mosé Da Prada and the discovery of tolcapone.
Borroni E; Borgulya J; Zürcher G
J Neural Transm Suppl; 1998; 52():XIII-XVI. PubMed ID: 9564601
[No Abstract] [Full Text] [Related]
38. The L-DOPA story revisited. Further surprises to be expected?
Foley P
J Neural Transm Suppl; 2000; (60):1-20. PubMed ID: 11205132
[TBL] [Abstract][Full Text] [Related]
39. Parkinson's disease: current scientific understanding, and John's story.
Froberg J
J Psychosoc Nurs Ment Health Serv; 2002 Oct; 40(10):30-7. PubMed ID: 12385197
[TBL] [Abstract][Full Text] [Related]
40. Role of dopamine receptors in neurological drug treatment.
Rinne UK
Ann Clin Res; 1988; 20(5):334-9. PubMed ID: 3218905
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
